Four main therapeutic keys for Parkinson’s disease: A mini review

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 286

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-22-7_002

تاریخ نمایه سازی: 20 مهر 1398

Abstract:

Objective(s): Parkinson’s disease (PD) is characterized by motor and cognitive dysfunctions. The progressive degeneration of dopamine-producing neurons that are present in the substantia nigra pars compacta (SNpc) has been the main focus of study and PD therapies since ages.Materials and Methods: In this manuscript, a systematic revision of experimental and clinical evidence of PD-associated cell process was conducted. Results: Classically, the damage in the dopaminergic neuronal circuits of SNpc is favored by reactive oxidative/nitrosative stress, leading to cell death. Interestingly, the therapy for PD has only focused on avoiding the symptom progression but not in finding a complete reversion of the disease. Recent evidence suggests that the renin-angiotensin system imbalance and neuroinflammation are the main keys in the progression of experimental PD. Conclusion: The progression of neurodegeneration in SNpc is due to the complex interaction of multiple processes. In this review, we analyzed the main contribution of four cellular processes and discussed in the perspective of novel experimental approaches. 

Authors

Daniel Hernandez-Baltazar

CONACYT-Instituto de Neuroetologia, Universidad Veracruzana, Xalapa, Veracruz, Mexico

Rasajna Nadella

IIIT Srikakulam, Rajiv Gandhi University of Knowledge Technologies (RGUKT); International collaboration ID:۱۸۴۰; India

Laura Mireya Zavala Flores

Centro de Investigacion Biomedica del Noreste. IMSS. Monterrey, Nuevo Leon. Mexico

Christian de Jesus Rosas-Jarquin

Instituto de Neuroetologia, Universidad Veracruzana. Xalapa, Veracruz, Mexico

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk ...
  • Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, ...
  • DeMaagd G, Philip A. Parkinson’s Disease and Its Management: Part ...
  • Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. ...
  • Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and ...
  • Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. ...
  • Vogt Weisenhorn DM, Giesert F, Wurst W. Diversity matters - ...
  • Mazzone P, Lozano A, Stanzione P, Galati S, Scarnati E, ...
  • Okun MS. Deep-brain stimulation for Parkinson’s disease. N Engl J ...
  • Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, ...
  • Aquilonius SM, Nyholm D. Development of new levodopa treatment strategies ...
  • Devos D, French DSG. Patient profile, indications, efficacy and safety ...
  • Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, ...
  • Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: ...
  • Cruz MP. Xadago (Safinamide): A Monoamine oxidase B inhibitor for ...
  • deSouza RM, Schapira A. Safinamide for the treatment of Parkinson’s ...
  • Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for ...
  • Borovac JA. Side effects of a dopamine agonist therapy for ...
  • Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: ...
  • Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress ...
  • Dias V, Junn E, Mouradian MM. The role of oxidative ...
  • Di Meo S, Reed TT, Venditti P, Victor VM. Role ...
  • Sovolyova N, Healy S, Samali A, Logue SE. Stressed to ...
  • Gonzalez-Hernandez T, Cruz-Muros I, Afonso-Oramas D, Salas-Hernandez J, Castro-Hernandez J. ...
  • Haddad D, Nakamura K. Understanding the susceptibility of dopamine neurons ...
  • Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, ...
  • Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, ...
  • Franco-Iborra S, Perier C. Neurodegeneration: The Size Takes It All. ...
  • Giguere N, Trudeau LE. [Axon arborization size is a key ...
  • Pacelli C, Giguere N, Bourque MJ, Levesque M, Slack RS, ...
  • Giguere N, Burke Nanni S, Trudeau LE. On cell loss ...
  • Venderova K, Park DS. Programmed cell death in Parkinson’s disease. ...
  • Van Laar VS, Berman SB. The interplay of neuronal mitochondrial ...
  • Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: ...
  • Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of ...
  • Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring ...
  • Grunewald A, Kumar KR, Sue CM. New insights into the ...
  • Yakhine-Diop SMS, Niso-Santano M, Rodriguez-Arribas M, Gomez-Sanchez R, Martinez-Chacon G, ...
  • Campbell P, Morris H, Schapira A. Chaperone-mediated autophagy as a ...
  • Zhang J, Cao R, Cai T, Aschner M, Zhao F, ...
  • Hughes AJ, Daniel SE, Lees AJ. The clinical features of ...
  • Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D. Activation of GSK-3beta and ...
  • Blanco-Alvarez VM, Lopez-Moreno P, Soto-Rodriguez G, Martinez-Fong D, Rubio H, ...
  • Duda P, Wisniewski J, Wojtowicz T, Wojcicka O, Jaskiewicz M, ...
  • Shin EJ, Hwang YG, Sharma N, Tran HQ, Dang DK, ...
  • Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for ...
  • Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. ...
  • Tang Y, Le W. Differential Roles of M1 and M2 ...
  • Stefanis L. alpha-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect ...
  • Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans ...
  • Ma MW, Wang J, Dhandapani KM, Brann DW. NADPH Oxidase ...
  • Flores-Martinez YM, Fernandez-Parrilla MA, Ayala-Davila J, Reyes-Corona D, Blanco-Alvarez VM, ...
  • Buffo A, Rite I, Tripathi P, Lepier A, Colak D, ...
  • Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. ...
  • Seri B, Garcia-Verdugo JM, Collado-Morente L, McEwen BS, Alvarez-Buylla A. ...
  • Kitamura Y, Inden M, Minamino H, Abe M, Takata K, ...
  • Nadella R, Voutilainen MH, Saarma M, Gonzalez-Barrios JA, Leon-Chavez BA, ...
  • Wright JW, Harding JW. Importance of the brain Angiotensin system ...
  • Labandeira-Garcia JL, Garrido-Gil P, Rodriguez-Pallares J, Valenzuela R, Borrajo A, ...
  • Dominguez-Meijide A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. ...
  • Rodriguez-Pallares J, Quiroz CR, Parga JA, Guerra MJ, Labandeira-Garcia JL. ...
  • Rodriguez-Pallares J, Rey P, Parga JA, Munoz A, Guerra MJ, ...
  • Chao J, Yang L, Buch S, Gao L. Angiotensin II ...
  • Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, ...
  • Garrido-Gil P, Rodriguez-Pallares J, Dominguez-Meijide A, Guerra MJ, Labandeira-Garcia JL. ...
  • Labandeira-Garcia JL, Rodriguez-Pallares J, Rodriguez-Perez AI, Garrido-Gil P, Villar-Cheda B, ...
  • Munoz A, Garrido-Gil P, Dominguez-Meijide A, Labandeira-Garcia JL. Angiotensin type ...
  • Rocha NP, Scalzo PL, Barbosa IG, de Campos-Carli SM, Tavares ...
  • Villar-Cheda B, Costa-Besada MA, Valenzuela R, Perez-Costas E, Melendez-Ferro M, ...
  • Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH. NG2 is ...
  • Stallcup WB. The NG2 proteoglycan: past insights and future prospects. ...
  • Belachew S, Chittajallu R, Aguirre AA, Yuan X, Kirby M, ...
  • Chung SH, Guo F, Jiang P, Pleasure DE, Deng W. ...
  • Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. ...
  • Chari DM, Blakemore WF. Efficient recolonisation of progenitor-depleted areas of ...
  • Magnus T, Carmen J, Deleon J, Xue H, Pardo AC, ...
  • Nait-Oumesmar B, Decker L, Lachapelle F, Avellana-Adalid V, Bachelin C, ...
  • Tamura Y, Kataoka Y, Cui Y, Takamori Y, Watanabe Y, ...
  • Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies ...
  • Carrascal L, Nunez-Abades P, Ayala A, Cano M. Role of ...
  • Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ. ...
  • Martinez B, Peplow PV. Neuroprotection by immunomodulatory agents in animal ...
  • Wang YL, Ju B, Zhang YZ, Yin HL, Liu YJ, ...
  • Ullah H, Khan H. Anti-Parkinson potential of silymarin: mechanistic insight ...
  • Zanforlin E, Zagotto G, Ribaudo G. The medicinal chemistry of ...
  • Kirik D, Cederfjall E, Halliday G, Petersen A. Gene therapy ...
  • Pignataro D, Sucunza D, Rico AJ, Dopeso-Reyes IG, Roda E, ...
  • نمایش کامل مراجع